January 17th, 2024: Ratio Therapeutics Announces $50M Series B ...

Jan 17, 2024 · Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90Million Since 2021 Launch. BOSTON, January 17, 2024 – Ratio Therapeutics Inc. …

CouponFollow Extension

$50
OFF

January 17th, 2024: Ratio Therapeutics Announces $50M Series B ...

6 days from now

Jan 17, 2024 · Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90Million Since 2021 Launch. BOSTON, January 17, 2024 – Ratio Therapeutics Inc. …

ratiotx.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

6 days from now

Jan 17, 2024 · Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment ... altered to bind to any antigen-specific target, while …

prnewswire.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

6 days from now

BOSTON, Jan. 17, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class …

yahoo.com

$50
OFF

Ratio Therapeutics Raises $50M For Tumor-targeting …

6 days from now

Jan 17, 2024 · Ratio Therapeutics raises $50M for tumor-targeting radiopharmaceuticals. ... Ratio Therapeutics Inc. has secured the backing to move its first drug candidate into clinical trials by …

bizjournals.com

$50
OFF

Ratio Therapeutics Secures $50M Series B To Develop Cancer …

6 days from now

Jan 18, 2024 · Boston-based pharmaceutical company Ratio Therapeutics has announced the completion of a $50 million Series B financing round to advance its targeted radiotherapies for …

builtinboston.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

6 days from now

BOSTON, Jan. 17, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class …

biospace.com

$50
OFF

Ratio Therapeutics Raises $50M In Series B Financing

6 days from now

Jan 17, 2024 · Ratio Therapeutics Raises $50M in Series B Financing ... The platforms are designed to deliver radioactive isotopes to cancer cells without added toxicity, with Trillium …

precisionmedicineonline.com

$50
OFF

Ratio Therapeutics Secures Funds For Cancer Radiotherapies

6 days from now

Jan 18, 2024 · Ratio Therapeutics has secured $50m in a Series B financing round, a significant move aimed at advancing targeted radiotherapies for cancer treatment. The funding, which …

pharmaceutical-technology.com

$50
OFF

Media - Ratio Therapeutics

6 days from now

Oct 23, 2024 · Ratio Therapeutics raises $50M for tumor-targeting radiopharmaceuticals. Boston Business Journal | January 17th, 2024. The Boston company has secured the backing to …

ratiotx.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

6 days from now

Jan 17, 2024 · Boston-Based Radiopharmaceutical Company Brings Total Financing to More Than $90 Million Since 2021 Launch. BOSTON, MA, USA I January 17, 2024 I Ratio …

pipelinereview.com

$50000000
OFF

Series B - Ratio Therapeutics - 2024-01-17 - Crunchbase

6 days from now

Jan 17, 2024 · Ratio Therapeutics raised $50000000 on 2024-01-17 in Series B. Search Crunchbase. ... Law360 — Boston's Ratio Therapeutics Raises $50M Series B For R&D . ...

crunchbase.com

$1.75
OFF

Novartis Strengthens Radiopharma Leadership With Ratio …

6 days from now

In May, Novartis acquired Mariana Oncology in a $1.75bn deal, inheriting the latter's lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer.

msn.com

$50
OFF

Ratio Therapeutics Announces $50M Series B Financing To …

6 days from now

BOSTON, January 17, 2024-- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for …

vcaonline.com

FAQs about January 17th, 2024: Ratio Therapeutics Announces $50M Series B ... Coupon?

Will ratio Therapeutics move its first drug candidate into clinical trials?

Ratio Therapeutics Inc. has secured the backing to move its first drug candidate into clinical trials by the end of this year. The Boston company is developing radiopharmaceuticals for the treatment and monitoring of cancers. ...

Why are radiation treatments most effective for lymphoma?

Radiation therapy is extremely effective for lymphomas. The reason is lymphomas are radiosensitive. It means that they respond very well to even moderate doses of radiation. In radiation therapy, high-energy X-rays are used to destroy the abnormal cells that cause cancer. ...

What does ratio Therapeutics do?

Developing best-in-class radiopharmaceuticals for cancer patients A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers. ...

Why is SSTR2 a key target for cancer treatment?

A protein overexpressed in various cancers, SSTR2 is a key target for therapies due to its role in enabling precise and targeted treatment. Novartis is already a key player in this field with its pioneering radiopharmaceutical Lutathera (lutetium Lu 177 dotatate), which also targets SSTR2. ...

Does radiation treatment for other reasons cause cancer?

Radiation treatment for various medical reasons, including cancer, aims to benefit patients. While it's designed to target specific cells, there's a minimal risk of developing secondary cancers due to radiation exposure. Healthcare professionals take precautions to minimize risks, but long-term effects can vary based on factors like radiation dose and individual health. ...

Are treatments customized for people of different sizes of prostate cancer?

As with most malignant tumors, choosing the most appropriate treatment for prostate tumors will depend on the stage of the disease and not just the size of the tumor. Let us observe that prostate cancer is a disordered proliferation of cells originating in the prostate and that have the property of invading adjacent organs and tissues and of spreading throughout the body, establishing neoplastic implants at a distance. In this context, treatment proposals include surgery, radiotherapy, brachytherapy, or even simply active surveillance (consists of observing the evolution of the tumor, initially without specific therapy), which can even be associated in a treatment proposal, depending on the stage and aggressiveness of the tumor. ...